Abacavir, Dolutegravir, and Lamivudine

Abacavir, Dolutegravir, and Lamivudine on the U.S. market: products, makers and brands

How Abacavir, Dolutegravir, and Lamivudine appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

1 company lists 2 Abacavir, Dolutegravir, and Lamivudine product records with the FDA, mostly as tablet; the earliest marketing or approval year on record is 2014. Brand names on the directory include Triumeq, Triumeq PD; the rest are generics.

Also listed with the FDA, not a patient dose form: Kit (3) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.

How widely Abacavir, Dolutegravir, and Lamivudine is used (Medicaid data)

A general measure of how commonly Abacavir, Dolutegravir, and Lamivudine is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Abacavir, Dolutegravir, and Lamivudine is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

How commonly is Abacavir, Dolutegravir, and Lamivudine prescribed? Of the 1,601 medications we measure, Abacavir, Dolutegravir, and Lamivudine ranks #630 by Medicaid prescriptions — more than 61% of them.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Abacavir, Dolutegravir, and Lamivudine, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 2 of 3 listed Abacavir, Dolutegravir, and Lamivudine NDCs with Medicaid activity.

Compare Abacavir, Dolutegravir, and Lamivudine products

A representative set of FDA-listed product records for Abacavir, Dolutegravir, and Lamivudine — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 2 of 2 products — FDA National Drug Code Directory. See every product, package size and price: browse all 2 Abacavir, Dolutegravir, and Lamivudine NDCs →

💵 What Abacavir, Dolutegravir, and Lamivudine costs pharmacies (NADAC benchmark)

The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.

Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.

Abacavir, Dolutegravir, and Lamivudine brand names

Abacavir, Dolutegravir, and Lamivudine is sold under 2 brand names in the FDA directory — Triumeq, Triumeq PD. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.

Who makes Abacavir, Dolutegravir, and Lamivudine: manufacturers and labelers

One company lists Abacavir, Dolutegravir, and Lamivudine products with the FDA. By number of product records, the largest are ViiV Healthcare Company. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Medications related to Abacavir, Dolutegravir, and Lamivudine